0001493152-14-002842.txt : 20140903 0001493152-14-002842.hdr.sgml : 20140903 20140903170039 ACCESSION NUMBER: 0001493152-14-002842 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140901 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events FILED AS OF DATE: 20140903 DATE AS OF CHANGE: 20140903 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Imprimis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001360214 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 450567010 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35814 FILM NUMBER: 141081099 BUSINESS ADDRESS: STREET 1: 12626 HIGH BLUFF DR. STREET 2: SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-704-4040 MAIL ADDRESS: STREET 1: 12626 HIGH BLUFF DR. STREET 2: SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: TRANSDEL PHARMACEUTICALS INC DATE OF NAME CHANGE: 20070912 FORMER COMPANY: FORMER CONFORMED NAME: Bywater Resources, Inc DATE OF NAME CHANGE: 20060421 8-K 1 form8k.htm CURRENT REPORT

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 1, 2014

 

IMPRIMIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35814   45-0567010
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

12626 High Bluff Drive, Suite 150    
San Diego, CA   92130
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 704-4040

 

N/A
(Former name or former address if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 
 

 

Item 5.02 Departure of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

(b)          On September 1, 2014, director Peter Kenny provided notice to Imprimis Pharmaceuticals, Inc. (the “Company”) of his resignation from the Board of Directors of the Company for personal reasons, effective as of that date. Mr. Kenny’s resignation is not due to any disagreement with the Company. In connection with Mr. Kenny’s resignation, he is also declining to stand for re-election to the Company’s Board of Directors at the Company’s 2014 annual stockholder meeting to be held on September 4, 2014.

 

Item 8.01 Other Events

 

On September 3, 2014, director nominee William A. Koefoed, Jr. provided notice to the Company that he is declining to stand for election to the Company’s Board of Directors at the Company’s 2014 annual stockholder meeting to be held on September 4, 2014. Mr. Koefoed, who is not a director of the Company but was nominated for election at the 2014 annual stockholder meeting, decided to withdraw from election to the Company’s Board of Directors for personal reasons and not due to any disagreement with the Company.

 

The Company’s Board of Directors does not expect to designate any substitute director nominees for election in place of Mr. Kenny or Mr. Koefoed at its 2014 annual stockholder meeting.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMPRIMIS PHARMACEUTICALS, INC.
     
Dated: September 3, 2014 By: /s/ Mark L. Baum
  Name: Mark L. Baum
  Title: Chief Executive Officer